United States: Solicitor General Sides With Sandoz On Interpretation Of Biosimilar Statute

The Solicitor General of the United States has filed an amicus brief in Sandoz Inc. v. Amgen Inc., asking the Supreme Court to grant certiorari and reverse the Federal Circuit's interpretation of one of the "patent dance" provisions of the biosimilar statute. In particular, the Solicitor General does not agree that the pre-marketing notice required by 21 USC § 262(l)(8)(A) cannot be given until the biosimilar product has been approved by the FDA. While not dispositive, this filing increases the odds that the Court will weigh in on this issue, and may increase the odds that the Supreme Court also will side with Sandoz.

The Neupogen® // Zarxio® Biosimilar Dispute

This case surrounds the first biosimilar product approved under the Biologics Price Competition and Innovation Act (BPCIA)–Sandoz' Zarxio® (filgrastim-sndz) product, which was approved as a biosimilar of Amgen's Neupogen® (filgrastim) product on March 6, 2015.

In the decision at issue, the Federal Circuit interpreted two of the "patent dance" provisions of the BPCIA:

  • whether 42 USC § 262(l)(2)(A) required Sandoz to provide Amgen with a copy of its biosimilar application and other information describing how its product is made

    • The court held it did not, finding the information exchange provisions optional, while noting that the BPCIA imposes consequences for not providing the information.

      • The Solicitor General agrees with the Federal Circuit's interpretation of § 262(l)(2)(A)
  • whether § 262(l)(8)(A) required Sandoz to wait until its biosimilar application was approved before giving Amgen 180 days prior notice of commercial marketing.

    • The court held it did, finding that pre-marketing notice cannot be given until the FDA has approved the biosimilar product.

      • The Solicitor General disagrees with the Federal Circuit's interpretation of § 262(l)(8)(A)

Sandoz petitioned the Supreme Court to review the Federal Circuit's decision on the second issue. In response, Amgen filed a conditional cross-petition for review of the Federal Circuit's decision on the first issue.

These articles discuss the previous proceedings in more detail:

The Solicitor General Weighs In

The Solicitor General's brief responds to the Supreme Court's June 20, 2016, invitation "to file a brief in this case expressing the views of the United States." Those views are aligned with Sandoz in this case.

The court of appeals erred in interpreting Subsection (l)(8)(A), but it correctly construed Subsection (l)(2)(A).

The Solicitor General urges the Court to take up the case for review, because:

The proper interpretation of those provisions has a significant impact on the operation of the BPCIA and the ability of aBLA applicants promptly to bring their biosimilars to the public. And because the provisions are integrally related, the Court should consider all of the questions presented together. Both the certiorari petition and conditional cross-petition therefore should be granted.

Pre-Marketing Notice May Be Given At Any Time

The Solicitor General reads § 262(l)(8)(A) as setting forth the latest date at which pre-marketing notice may be given, and disagrees with the Federal Circuit's interpretation that notice cannot be given until the biosimilar product is approved.

According to the Solicitor General's explanation of the patent dance framework, the pre-marketing notice serves two functions:

  • Permitting the reference product sponsor (e.g., Amgen in this case) to bring suit on any "Round 2" patents and
  • Permitting the reference product sponsor to seek a preliminary injunction until the court decides any "Round 2" patent issues.

With this limited purpose in mind, the Solicitor General criticizes the Federal Circuit's interpretation:

[U]nder the Federal Circuit's reading, the owner of a biosimilar with an effective license could be forced to wait 180 days after FDA has authorized it to commence marketing, even if the sponsor had no arguably valid infringement claim to warrant such delay.

(emphasis added).

Responding to the court's rationale that requiring a licensed product would ensure that the Round 2 litigation would reflect a "fully crystallized controversy," the Solicitor General argues that Congress already made "policy judgments" on this issue when it made the submission of an aBLA an act of infringement. The Solicitor General also emphasizes numerous ways in which the BPCIA gives the biosimilar applicant control over the "Round 1" patent litigation, and paints an overall picture of Congressional intent to permit all patent infringement issues to be resolved early.

The Remedy For Failing To Give Pre-Marketing Notice
Is A Patent Infringement Suit

The Solicitor General also takes issue with the remedy imposed by the Federal Circuit for Sandoz' purportedly defective pre-marketing notice–the injunction that kept Zarxio® off the market until 180 days after FDA approval.

Nothing in the BPCIA creates a cause of action to enforce Section 262(l)(8)(A)'s notice provision. .... The sponsor's proper course if notice is not given under Section 262(l)(8)(A) is therefore the course contemplated by the BPCIA: an immediate patent-infringement action. See 35 U.S.C. 271(e)(2)(C); 42 U.S.C. 262(l)(9)(B).

The Realities Of Biosimilar Patent Litigation

The relevant provisions of the patent infringement statute (35 USC § 271(e)(2)) hold:

(2) It shall be an act of infringement to submit—
(C)(i) with respect to a patent that is identified in the list of patents described in [42 U.S.C. § 262(l)(3) including as provided under 42 U.S.C. § 262(l)(7)], an application seeking approval of a biological product, or
(ii) if the applicant for the application fails to provide the application and information required under [42 U.S.C. § 262(l)(2)(A)], an application seeking approval of a biological product for a patent that could be identified pursuant to [42 U.S.C. § 262(l)(3)(A)(i)],
if the purpose of such submission is to obtain approval under such Act to engage in the commercial manufacture, use, or sale of a drug, veterinary biological product, or biological product
claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.

However, § 262(l)(3)(A)(i) refers to "a list of patents for which the reference product sponsor believes a claim of patent infringement could reasonably be asserted ... if a person ... engaged in the making, using, offering to sell, selling, or importing into the United States of the biological product that is the subject of the subsection (k) application." Thus, if the biosimilar Applicant does not provide the § 262(l)(2)(A) information, the reference product sponsor must decide whether to bring suit and which patents to assert based on whatever information is available to it about the biosimilar product.

While patent owners do bear the burden of policing the commercial marketplace for infringing products, requiring a reference product sponsor to conduct its own pre-litigation investigations of a confidential aBLA product imposes a much higher burden, and tips any balance thought to be embodied in the BCPIA far in favor of biosimilar applicants.

Supreme Court Denies Cert in Amgen v. Apotex

On December 12, 2016, the Supreme Court denied certiorari in Amgen v. Apotex, where the Federal Circuit applied its interpretation of the pre-marketing notice requirement in the dispute between Amgen and Apotex over Neupogen® (filgrastim) and Neulasta® (pegfilgrastim). Does this signal the Court's view on this issue, or just the Court's determination that it can fully address the issue in Amgen v. Sandoz?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Akin Gump Strauss Hauer & Feld LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Akin Gump Strauss Hauer & Feld LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions